Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma

References

• Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am. 2020;100(1):1–12. doi:10.1016/j.suc.2019.09.005
   PubMed Web of Science ®Google Scholar
• Gershenwald JE, Guy GP Jr. Stemming the rising incidence of melanoma: calling prevention to action. J Natl Cancer Inst. 2016;108(1). doi: 10.1093/jnci/djv381
   Google Scholar
• Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971–984. doi: 10.1016/S0140-6736(18)31559-9
   PubMed Web of Science ®Google Scholar
• SEER explorer: an interactive website for SEER cancer statistics [internet]. Surveillance Research Program, National Cancer Institute; [cited 2023 May 1]. Available from: https://seer.cancer.gov/statistics-network/explorer/
   Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines®) for melanoma: cutaneous V 2.2023 [internet]. National Comprehensive Cancer Network, Inc; 2023 [cited 2023 Jul 1]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
   Google Scholar
• Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–492. doi: 10.3322/caac.21409
   PubMed Web of Science ®Google Scholar
• Clark WH, Jr., From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705–727.
   PubMed Web of Science ®Google Scholar
• Yun SJ, Gimotty PA, Hwang WT, et al. High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma. Am J Surg Pathol. 2011;35(2):235–242. doi: 10.1097/PAS.0b013e3182036ccd
   PubMed Web of Science ®Google Scholar
• Scolyer RA, Thompson JF. Desmoplastic melanoma: a heterogeneous entity in which subclassification as “pure” or “mixed” may have important prognostic significance. Ann Surg Oncol. 2005;12(3):197–199. doi:10.1245/ASO.2005.12.914
   PubMed Web of Science ®Google Scholar
• Zito Marino F, Ascierto PA, Rossi G, et al. Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy? Expert Opin Biol Ther. 2017;17(6):735–746. doi: 10.1080/14712598.2017.1309387
   PubMed Web of Science ®Google Scholar
• Clark WH, Jr., Elder DE, Guerry Dt, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893–1904. doi: 10.1093/jnci/81.24.1893
   PubMed Web of Science ®Google Scholar
• Urso C. Are growth phases exclusive to cutaneous melanoma? J Clin Pathol. 2004;57(5):560. doi:10.1136/jcp.2003.014852
   PubMed Web of Science ®Google Scholar
• Teixido C, Gonzalez-Cao M, Karachaliou N, et al. Predictive factors for immunotherapy in melanoma. Ann Transl Med. 2015;3(15):208. doi: 10.3978/j.issn.2305-5839.2015.05.07
   PubMedGoogle Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9(1):204. doi: 10.1186/1479-5876-9-204
   PubMedGoogle Scholar
• Shon W, Frishberg D. P., Gershenwald, J, et al. Protocol for the examination of excision specimens from patients with melanoma of the skin. CAP. 2021;4.2.0.0;5.
   Google Scholar
• Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–250. doi: 10.1016/j.jaad.2018.08.055
   PubMed Web of Science ®Google Scholar
• Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24(6):311–335. doi: 10.1097/PAP.0000000000000161
   PubMed Web of Science ®Google Scholar
• Fortes C, Mastroeni S, Mannooranparampil TJ, et al. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. Melanoma Res. 2015;25(4):306–311. doi: 10.1097/CMR.0000000000000164
   PubMed Web of Science ®Google Scholar
• Monshizadeh L, Hanikeri M, Beer TW, et al. A critical review of melanoma pathology reports for patients referred to the Western Australian melanoma advisory service. Pathology. 2012;44(5):441–447. doi: 10.1097/PAT.0b013e328355767e
   PubMed Web of Science ®Google Scholar
• Moore MR, Friesner ID, Rizk EM, et al. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Sci Rep. 2021;11(1):2809. doi: 10.1038/s41598-021-82305-1
   PubMed Web of Science ®Google Scholar
• Chatziioannou E, Rossner J, Aung TN, et al. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine. 2023;93:104644. doi: 10.1016/j.ebiom.2023.104644
   PubMed Web of Science ®Google Scholar
• Hussaini HM, Seo B, Rich AM. Immunohistochemistry and immunofluorescence. Methods Mol Biol. 2023;2588:439–450.
   PubMedGoogle Scholar
• Maibach F, Sadozai H, Seyed Jafari SM, et al. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020;11:2105. doi: 10.3389/fimmu.2020.02105
   PubMed Web of Science ®Google Scholar
• Nirmal AJ, Maliga Z, Vallius T, et al. The spatial landscape of progression and immunoediting in primary melanoma at single-cell resolution. Cancer Discov. 2022;12(6):1518–1541. doi: 10.1158/2159-8290.CD-21-1357
   PubMed Web of Science ®Google Scholar
• Halse H, Colebatch AJ, Petrone P, et al. Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. Sci Rep. 2018;8(1):11158. doi: 10.1038/s41598-018-28944-3
   PubMedGoogle Scholar
• Parra ER, Uraoka N, Jiang M, et al. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep. 2017;7(1):13380. doi: 10.1038/s41598-017-13942-8
   PubMed Web of Science ®Google Scholar
• Fisher KE, Cohen C, Siddiqui MT, et al. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. Hum Pathol. 2014;45(11):2281–2293. doi: 10.1016/j.humpath.2014.07.014
   PubMed Web of Science ®Google Scholar
• Tan WCC, Nerurkar SN, Cai HY, et al. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond). 2020;40(4):135–153. doi: 10.1002/cac2.12023
   PubMed Web of Science ®Google Scholar
• Lyons YA, Wu SY, Overwijk WW, et al. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precis Oncol. 2017;1(1):26. doi: 10.1038/s41698-017-0031-0
   PubMedGoogle Scholar
• Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–2259. doi: 10.1172/JCI73639
   PubMed Web of Science ®Google Scholar
• Hyatt G, Melamed R, Park R, et al. Gene expression microarrays: glimpses of the immunological genome. Nat Immunol. 2006;7(7):686–691. doi: 10.1038/ni0706-686
   PubMed Web of Science ®Google Scholar
• Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189–196. doi: 10.1126/science.aad0501
   PubMed Web of Science ®Google Scholar
• Fattore L, Ruggiero CF, Liguoro D, et al. Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma. Cell Death Dis. 2019;10(11):827. doi: 10.1038/s41419-019-2048-5
   PubMedGoogle Scholar
• Stahl PL, Salmen F, Vickovic S, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016;353(6294):78–82. doi: 10.1126/science.aaf2403
   PubMed Web of Science ®Google Scholar
• Bennett HM, Stephenson W, Rose CM, et al. Single-cell proteomics enabled by next-generation sequencing or mass spectrometry. Nat Methods. 2023;20(3):363–374. doi: 10.1038/s41592-023-01791-5
   PubMed Web of Science ®Google Scholar
• Simiczyjew A, Dratkiewicz E, Mazurkiewicz J, et al. The influence of tumor microenvironment on immune escape of melanoma. Int J Mol Sci. 2020;21(21):8359. doi: 10.3390/ijms21218359
   PubMed Web of Science ®Google Scholar
• Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236–250. doi:10.1016/j.semcancer.2019.08.002
   PubMed Web of Science ®Google Scholar
• Pfefferle A, Jacobs B, Haroun-Izquierdo A, et al. Deciphering natural killer cell homeostasis. Front Immunol. 2020;11:812. doi: 10.3389/fimmu.2020.00812
   PubMedGoogle Scholar
• Lee H, Da Silva IP, Palendira U, et al. Targeting NK cells to enhance melanoma response to immunotherapies. Cancers (Basel). 2021;13(6):1363. doi: 10.3390/cancers13061363
   PubMed Web of Science ®Google Scholar
• Pieniazek M, Matkowski R, Donizy P. Macrophages in skin melanoma-the key element in melanomagenesis (Review). Oncol Lett. 2018;15(4):5399–5404. doi:10.3892/ol.2018.8021
   PubMed Web of Science ®Google Scholar
• Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. doi: 10.1038/bjc.2011.189
   PubMed Web of Science ®Google Scholar
• Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070–1080. doi: 10.1158/0008-5472.CAN-11-3218
   PubMed Web of Science ®Google Scholar
• Yamshchikov GV, Mullins DW, Chang CC, et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol. 2005;174(11):6863–6871. doi: 10.4049/jimmunol.174.11.6863
   PubMed Web of Science ®Google Scholar
• Lee N, Zakka LR, Mihm MC Jr., et al. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016;48(2):177–187. doi: 10.1016/j.pathol.2015.12.006
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792. doi:10.1038/cddis.2015.162
   PubMed Web of Science ®Google Scholar
• Yonick DV, Ballo RM, Kahn E, et al. Predictors of positive sentinel lymph node in thin melanoma. Am J Surg. 2011;201(3):324–327. discussion 327–328. doi: 10.1016/j.amjsurg.2010.09.011
   PubMed Web of Science ®Google Scholar
• Zaladonis A, Farma J, Hill M, et al. A retrospective, observational analysis of tumor infiltrating lymphocytes and tumor regression in melanoma. J Surg Res. 2021;267:203–208. doi: 10.1016/j.jss.2021.05.008
   PubMed Web of Science ®Google Scholar
• Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31(33):4252–4259. doi: 10.1200/JCO.2013.51.3002
   PubMed Web of Science ®Google Scholar
• Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678–2683. doi: 10.1200/JCO.2011.37.8539
   PubMed Web of Science ®Google Scholar
• Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25(7):869–875. doi: 10.1200/JCO.2006.08.9755
   PubMed Web of Science ®Google Scholar
• Subramanian S, Han G, Olson N, et al. Regression is significantly associated with outcomes for patients with melanoma. Surgery. 2021;170(5):1487–1494. doi: 10.1016/j.surg.2021.05.010
   PubMed Web of Science ®Google Scholar
• Subramanian S, Han G, Olson N, et al. Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence-free survival. J Surg Oncol. 2022;125(2):229–238. doi: 10.1002/jso.26678
   PubMed Web of Science ®Google Scholar
• Aung PP, Nagarajan P, Prieto VG. Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Lab Invest. 2017;97(6):657–668. doi:10.1038/labinvest.2017.8
   PubMed Web of Science ®Google Scholar
• Straker RJ 3rd, Krupp K, Sharon CE, et al. Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort. Ann Surg Oncol. 2022;29(8):5207–5216. doi: 10.1245/s10434-022-11478-4
   PubMed Web of Science ®Google Scholar
• Morrison SL, Han G, Elenwa F, et al. Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma? Cancer. 2022;128(7):1418–1428. doi: 10.1002/cncr.34013
   PubMed Web of Science ®Google Scholar
• Mackensen A, Ferradini L, Carcelain G, et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993;53(15):3569–3573. doi: 10.1097/00008390-199309002-00106
   PubMed Web of Science ®Google Scholar
• Osella-Abate S, Conti L, Annaratone L, et al. Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma. Pathology. 2019;51(5):487–493. doi: 10.1016/j.pathol.2019.04.001
   PubMed Web of Science ®Google Scholar
• Cintolo JA, Gimotty P, Blair A, et al. Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol. 2013;20(11):3610–3617. doi: 10.1245/s10434-013-3086-3
   PubMed Web of Science ®Google Scholar
• Aivazian K, Ahmed T, El Sharouni MA, et al. Histological regression in melanoma: impact on sentinel lymph node status and survival. Mod Pathol. 2021;34(11):1999–2008. doi: 10.1038/s41379-021-00870-2
   PubMed Web of Science ®Google Scholar
• Tas F, Erturk K. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma. J Cancer Res Clin Oncol. 2021;147(9):2721–2729. doi:10.1007/s00432-021-03565-y
   PubMed Web of Science ®Google Scholar
• El Sharouni MA, Stodell MD, Ahmed T, et al. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Ann Oncol. 2021;32(3):375–383. doi: 10.1016/j.annonc.2020.11.015
   PubMed Web of Science ®Google Scholar
• Guggenheim M, Dummer R, Jung FJ, et al. The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma–a retrospective analysis of 392 cases. Br J Cancer. 2008;98(12):1922–1928. doi: 10.1038/sj.bjc.6604407
   PubMed Web of Science ®Google Scholar
• Mandala M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 2009;45(14):2537–2545. doi: 10.1016/j.ejca.2009.05.034
   PubMed Web of Science ®Google Scholar
• Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107(10):2436–2445. doi: 10.1002/cncr.22295
   PubMed Web of Science ®Google Scholar
• Borkowska AM, Szumera-Cieckiewicz A, Chraszczewska M, et al. Clinical significance of tumor microenvironment in acral melanoma: a large single-institution study of caucasians. J Clin Med. 2021;10(7):1452. doi: 10.3390/jcm10071452
   PubMed Web of Science ®Google Scholar
• Angeramo CA, Laxague F, Armella ED, et al. Tumor-infiltrating lymphocytes in patients with Melanoma: which is its prognostic value? Indian J Surg Oncol. 2021;12(4):770–775. doi: 10.1007/s13193-021-01427-0
   PubMed Web of Science ®Google Scholar
• Donizy P, Kaczorowski M, Halon A, et al. Paucity of tumor-infiltrating lymphocytes is an unfavorable prognosticator and predicts lymph node metastases in cutaneous melanoma patients. Anticancer Res. 2015;35(1):351–358. doi: 10.1155/2015/975436
   PubMed Web of Science ®Google Scholar
• Duprat JP, Brechtbulh ER, Costa de Sa B, et al. Absence of tumor-infiltrating lymphocyte is a reproducible predictive factor for sentinel lymph node metastasis: a multicenter database study by the brazilian melanoma group. PLoS One. 2016;11(2):e0148160. doi: 10.1371/journal.pone.0148160
   PubMed Web of Science ®Google Scholar
• Allard-Coutu A, Dobson V, Schmitz E, et al. The evolution of the sentinel node biopsy in melanoma. Life (Basel). 2023;13(2):489. doi: 10.3390/life13020489
   PubMed Web of Science ®Google Scholar
• Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American joint committee on cancer staging system. Ann Surg Oncol. 2005;12(4):282–288. doi: 10.1245/ASO.2005.05.016
   PubMed Web of Science ®Google Scholar
• Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the melanoma institute Australia nomogram. J Clin Oncol. 2020;38(24):2719–2727. doi: 10.1200/JCO.19.02362
   PubMed Web of Science ®Google Scholar
• Fortes C, Mastroeni S, Caggiati A, et al. High level of TILs is an independent predictor of negative sentinel lymph node in women but not in men. Arch Dermatol Res. 2021;313(1):57–61. doi: 10.1007/s00403-020-02067-0
   PubMed Web of Science ®Google Scholar
• Sinnamon AJ, Sharon CE, Song Y, et al. The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex. J Am Acad Dermatol. 2018;79(2):245–251. doi: 10.1016/j.jaad.2018.02.066
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MC Jr., Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303–1310. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1303:AID-CNCR12>3.0.CO;2-5
   PubMed Web of Science ®Google Scholar
• Weiss SA, Hanniford D, Hernando E, et al. Revisiting determinants of prognosis in cutaneous melanoma. Cancer. 2015;121(23):4108–4123. doi: 10.1002/cncr.29634
   PubMed Web of Science ®Google Scholar
• Yang J, Lian JW, Chin YH, et al. Assessing the prognostic significance of tumor-infiltrating lymphocytes in patients with melanoma using pathologic features identified by natural language processing. JAMA Netw Open. 2021;4(9):e2126337. doi: 10.1001/jamanetworkopen.2021.26337
   PubMed Web of Science ®Google Scholar
• Burton AL, Roach BA, Mays MP, et al. Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg. 2011;77(2):188–192. doi: 10.1177/000313481107700219
   PubMed Web of Science ®Google Scholar
• van Houdt IS, Sluijter BJ, Moesbergen LM, et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer. 2008;123(3):609–615. doi: 10.1002/ijc.23543
   PubMed Web of Science ®Google Scholar
• Fu Q, Chen N, Ge C, et al. Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019;8(7):1593806. doi: 10.1080/2162402X.2019.1593806
   PubMed Web of Science ®Google Scholar
• Ladanyi A, Sebestyen T, Mohos A, et al. Ectopic lymphoid structures in primary cutaneous melanoma. Pathol Oncol Res. 2014;20(4):981–985. doi: 10.1007/s12253-014-9784-8
   PubMed Web of Science ®Google Scholar
• Weiss SA, Han SW, Lui K, et al. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Hum Pathol. 2016;57:116–125. doi: 10.1016/j.humpath.2016.07.008
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi: 10.1056/NEJMoa1709684
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi: 10.1056/NEJMoa1104621
   PubMed Web of Science ®Google Scholar
• Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol. 2015;33:23–35. doi:10.1016/j.coi.2015.01.006
   PubMed Web of Science ®Google Scholar
• Wong PF, Wei W, Smithy JW, et al. Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. Clin Cancer Res. 2019;25(8):2442–2449. doi: 10.1158/1078-0432.CCR-18-2652
   PubMed Web of Science ®Google Scholar
• Stephens MR, Aderbigbe O, Xu W, et al. Association between metastatic melanoma response to checkpoint inhibitor therapy and tumor-infiltrating lymphocyte classification on primary cutaneous melanoma biopsies. JAMA Dermatol. 2023;159(2):215–216. doi: 10.1001/jamadermatol.2022.4959
   PubMed Web of Science ®Google Scholar
• Klein S, Mauch C, Brinker K, et al. Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600(E/K) mutated malignant melanomas. Sci Rep. 2021;11(1):1834. doi: 10.1038/s41598-021-81330-4
   PubMed Web of Science ®Google Scholar
• Ziemys A, Kim M, Menzies AM, et al. Integration of digital pathologic and transcriptomic analyses connects tumor-infiltrating lymphocyte spatial density with clinical response to BRAF inhibitors. Front Oncol. 2020;10:757. doi: 10.3389/fonc.2020.00757
   PubMed Web of Science ®Google Scholar
• Gide TN, Quek C, Menzies AM, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35(2):238–255 e236. doi: 10.1016/j.ccell.2019.01.003
   PubMed Web of Science ®Google Scholar
• Gide TN, Paver EC, Yaseen Z, et al. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. Oncoimmunology. 2023;12(1):2261248. doi: 10.1080/2162402X.2023.2261248
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi: 10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18(5):1386–1394. doi: 10.1158/1078-0432.CCR-11-2479
   PubMed Web of Science ®Google Scholar
• Huang AC, Orlowski RJ, Xu X, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–461. doi: 10.1038/s41591-019-0357-y
   PubMed Web of Science ®Google Scholar
• Riaz N, Havel JJ, Makarov V, et al. Tumor and microenvironment evolution during immunotherapy with Nivolumab. Cell. 2017;171(4):934–949 e916. doi: 10.1016/j.cell.2017.09.028
   PubMed Web of Science ®Google Scholar
• Roh W, Chen PL, Reuben A, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9(379). doi: 10.1126/scitranslmed.aah3560
   Web of Science ®Google Scholar
• Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–3452. doi: 10.1172/JCI87324
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691–2697. doi:10.1200/JCO.2012.41.6750
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi: 10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Watson AS, Goutam S, Stukalin I, et al. Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or combination immunotherapy. JAMA Netw Open. 2022;5(12):e2245596. doi: 10.1001/jamanetworkopen.2022.45596
   PubMed Web of Science ®Google Scholar
• Stephens MR, Asdourian MS, Jacoby TV, et al. Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma. J Am Acad Dermatol. 2023;89(1):140–142. doi: 10.1016/j.jaad.2023.01.040
   PubMedGoogle Scholar
• Robert L, Harview C, Emerson R, et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology. 2014;3(6):e29244. doi: 10.4161/onci.29244
   PubMed Web of Science ®Google Scholar
• Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017;77(6):1322–1330. doi: 10.1158/0008-5472.CAN-16-2324
   PubMed Web of Science ®Google Scholar
• Asher N, Ben-Betzalel G, Lev-Ari S, et al. Real world outcomes of ipilimumab and nivolumab in patients with metastatic melanoma. Cancers (Basel). 2020;12(8):2329. doi: 10.3390/cancers12082329
   PubMed Web of Science ®Google Scholar
• Sinnamon AJ, Neuwirth MG, Bartlett EK, et al. Predictors of false negative sentinel lymph node biopsy in trunk and extremity melanoma. J Surg Oncol. 2017;116(7):848–855. doi: 10.1002/jso.24743
   PubMed Web of Science ®Google Scholar
• Moody JA, Ali RF, Carbone AC, et al. Complications of sentinel lymph node biopsy for melanoma – a systematic review of the literature. Eur J Surg Oncol. 2017;43(2):270–277. doi: 10.1016/j.ejso.2016.06.407
   PubMed Web of Science ®Google Scholar
• Sinnamon AJ, Song Y, Sharon CE, et al. Prediction of residual nodal disease at completion dissection following positive sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2018;25(12):3469–3475. doi: 10.1245/s10434-018-6647-7
   PubMed Web of Science ®Google Scholar
• Das A, Ghose A, Naicker K, et al. Advances in adoptive T-cell therapy for metastatic melanoma. Curr Res Transl Med. 2023;71(3):103404. doi: 10.1016/j.retram.2023.103404
   PubMed Web of Science ®Google Scholar
• Mason R, Au L, Ingles Garces A, et al. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother. 2019;20(9):1135–1152. doi: 10.1080/14656566.2019.1601700
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233–240. doi:10.1016/j.coi.2009.03.002
   PubMed Web of Science ®Google Scholar
• Goff SL, Dudley ME, Citrin DE, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol. 2016;34(20):2389–2397. doi: 10.1200/JCO.2016.66.7220
   PubMed Web of Science ®Google Scholar
• van den Berg JH, Heemskerk B, van Rooij N, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020;8(2). doi: 10.1136/jitc-2020-000848
   PubMed Web of Science ®Google Scholar
• Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656–2666. doi: 10.1200/JCO.21.00612
   PubMed Web of Science ®Google Scholar